- Home
- MSPR vs APM Comparison
MSPR vs APM Comparison
Compare MSPR & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSPR
- APM
- Stock Information
- Founded
- MSPR 2014
- APM 2010
- Country
- MSPR United States
- APM United Kingdom
- Employees
- MSPR N/A
- APM N/A
- Industry
- MSPR
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- MSPR
- APM Health Care
- Exchange
- MSPR NYSE
- APM Nasdaq
- Market Cap
- MSPR 4.9M
- APM 4.1M
- IPO Year
- MSPR N/A
- APM 2018
- Fundamental
- Price
- MSPR $2.16
- APM $1.15
- Analyst Decision
- MSPR
- APM
- Analyst Count
- MSPR 0
- APM 0
- Target Price
- MSPR N/A
- APM N/A
- AVG Volume (30 Days)
- MSPR 203.5K
- APM 7.0M
- Earning Date
- MSPR 11-14-2024
- APM 12-20-2024
- Dividend Yield
- MSPR N/A
- APM N/A
- EPS Growth
- MSPR N/A
- APM N/A
- EPS
- MSPR N/A
- APM 0.00
- Revenue
- MSPR $10,734,000.00
- APM N/A
- Revenue This Year
- MSPR $293,208.70
- APM $157,729.10
- Revenue Next Year
- MSPR N/A
- APM N/A
- P/E Ratio
- MSPR N/A
- APM $345.64
- Revenue Growth
- MSPR 217.86
- APM N/A
- 52 Week Low
- MSPR $1.43
- APM $0.46
- 52 Week High
- MSPR $66.00
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- MSPR N/A
- APM 47.12
- Support Level
- MSPR N/A
- APM $1.21
- Resistance Level
- MSPR N/A
- APM $1.30
- Average True Range (ATR)
- MSPR 0.00
- APM 0.75
- MACD
- MSPR 0.00
- APM -0.06
- Stochastic Oscillator
- MSPR 0.00
- APM 4.58
About MSPR MSP RECOVERY INC
MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services. It offers an antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions platform to recover any claims where the law places primary payment responsibility on another payer.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.